London School of Hygiene & Tropical Medicine Malaria Centre

Safety of artemisinin-based combination therapies


10 October 2014
Video and presentations now available online from ACT Consortium webinar

View the original story on the ACT Consortium web site.

The ACT Consortium recently held an interactive session on the safety of artemisinin-based combination therapies (ACTs) on 7 October 2014.




Clinical trials are not suitable to identify rare, potentially serious adverse effects of drugs, or to define their safety in high risk populations.

Artemisinin-based combination therapies (or ACTs) are considered safe, but there are concerns over their potential to cause damage to parts of the brain. There is also a concern about their safety in patients infected with HIV.  Collating safety data is a challenge in Africa, where most antimalarials are used and more vulnerable populations reside.

The Safety Data Collection Tools for Real-World Reporting developed by the ACT Consortium are the first step to providing more resources for researchers seeking user-friendly methods to evaluate antimalarial safety.

Any feedback or questions? Please contact debora [dot] miranda [at] lshtm [dot] ac [dot] uk (Debora Miranda.)